Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

First US patient receives LVAS using Mag-Lev technology

Terumo Heart : 22 August, 2008  (Company News)
The first US patient implanted with a DuraHeart Left Ventricular Assist System (LVAS) from Terumo Heart has been discharged homefrom the University of Michigan Health System, 15 days after receiving the device.
The patient is a 62-year-old man from Livonia, Michigan, who has been suffering from heart failure for nearly 20 years. He is the first US patient to receive a ventricular assist system that utilises advanced magnetic levitation (Mag-Lev), a new, innovative type of technology.

Dr Pagani, national co-principal investigator for the US pivotal trial of the DuraHeart LVAS commented on the recent discharge. 'We are extremely pleased with the performance of the DuraHeart and the recovery of our patient to an excellent functional state to permit discharge. We look forward to expanding upon our early experience with the DuraHeart in the near future.'

The goal of these devices is to return the patient back to a relatively normal lifestyle and to provide improved 'quality of life.' 'We are delighted that the FDA has allowed us to begin this trial with no restriction on patient discharge, which has not been true of some of the other devices currently conducting Trials in the United States,' said Chisato Nojiri, MD, PhD, chief executive officer for Terumo Heart.

Earlier generation Left Ventricular Assist devices are prone to haemolysis, blood clots and mechanical failure. Significant advances have been made in the DuraHeart LVAS to potentially overcome these problems. Dr Nojiri explained: 'We have a unique pump design that combines advanced ‘Mag-Lev’ technology and a centrifugal pump. The ‘Mag-Lev’ allows for the complete elimination of mechanical contact within the blood flow path, minimising the chance of mechanical failure. This is expected to significantly improve the clinical performance and long-term potential of this type of therapy.'

The device has been used in more than 70 patients in Europe with the longest ongoing support over three years.

The DuraHeart Bridge-to-Transplant Pivotal Trial is a multi-centre, prospective, non-randomized study of 140 patients and will include up to 40 centrre. The device is intended to provide cardiac support for patients awaiting transplant who are at risk of death due to end-stage left ventricular failure. The National Co-Principal Investigators are Francis Pagani, MD, PhD, from the University of Michigan and Yoshifumi Naka, MD, PhD, from Columbia Presbyterian Hospital in New York.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 ProHealthServiceZone.com
Netgains Logo